Furthermore, using similar dosage regimens, the TLR7 agonist, Imiquimod, reduced experimental autoimmune encephalomyelitis and increased splenic IFN-β production16. The gene discussed is IFNB1; the disease is experimental autoimmune encephalomyelitis.